{"id":229167,"date":"2025-12-18T00:00:00","date_gmt":"2025-12-18T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/47041184-medtech-urological-devices-market-insights-asia\/"},"modified":"2026-04-14T10:02:28","modified_gmt":"2026-04-14T10:02:28","slug":"47042558-medtech-urological-devices-market-insights-asia-pacific","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/47042558-medtech-urological-devices-market-insights-asia-pacific\/","title":{"rendered":"Urological Devices &#8211; Market Insights &#8211; Asia Pacific"},"content":{"rendered":"<p>Driven by rising kidney stone prevalence and an aging population, the Asia Pacific urological device market will grow at a modest rate through 2034. Other contributing factors for growth include an increasing prevalence of obesity, adoption of premium devices, and the growing availability of less invasive treatment options. Moreover, rising use of minimally invasive laser treatments in China and India\u2014where these techniques have been underpenetrated, will result in increased adoption of associated devices. However, <abbr title=\"Average Selling Price\">ASP<\/abbr> declines due to price-based competition will continue to hamper some segments within the Asia Pacific <abbr title=\"Gastrointestinal\">GI<\/abbr> endoscopy device market. In addition, reimbursement challenges, litigation risks tied to genitourinary meshes, and healthcare budget constraints will limit uptake of newer, premium-priced technologies.<\/p>\n<p>This Medtech 360 Report provides comprehensive data and analysis on the state of the market for urological devices in Asia Pacific from 2019 through 2034.<\/p>\n<p class=\"question-statement\"><strong>Minimally invasive treatment volumes will significantly increase over the forecast period in the Asia Pacific urological device market.<\/strong><\/p>\n<p>What factors contribute to the increase of minimally invasive treatments?<\/p>\n<p>How have minimally invasive treatment options changed the <abbr title=\"Benign Prostatic Hyperplasia\">BPH<\/abbr> device market?<\/p>\n<p>Which market segments will see the greatest adoption of minimally invasive treatments?<\/p>\n<p class=\"question-statement\"><strong>Partnership<\/strong><b> agreements and acquisitions have been altering the competitive landscape.<\/b><\/p>\n<p>What are the most relevant recent acquisitions affecting the market?<\/p>\n<p>How will product portfolios be affected as a result of these acquisitions?<\/p>\n<p>What are the key focus areas of partnership agreements in this domain?<\/p>\n<p><strong>Ongoing clinical studies and research continue to affect procedure trends, and thus device trends.<\/strong><\/p>\n<p>What do recent studies indicate regarding the outlook of existing techniques for treating prostate cancer, kidney stones, and <abbr title=\"Benign Prostatic Hyperplasia\">BPH<\/abbr>?<\/p>\n<p>What upcoming novel treatments are expected to compete with existing methods of treatment?<\/p>\n<p class=\"question-statement\"><b>The rising adoption of flexible endoscopy in this market will spur growth in multiple device segments.<\/b><\/p>\n<p>Which flexible endoscopes see a raise in their sales, and what are the reasons for it?<\/p>\n<p>How will the stone management device market be impacted by growth in flexible endoscope use?<\/p>\n<p>Will any markets be negatively impacted by the growing use of flexible endoscopy?<\/p>\n<p><strong>Premium devices and their adoption will influence market trends.<\/strong><\/p>\n<p>Which markets are going to be affected by preference for premium variants of devices?<\/p>\n<p>What circumstances hinder the uptake of premium devices in the Asia Pacific region?<\/p>\n","protected":false},"template":"","class_list":["post-229167","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-therapy-area-urological-devices","medtech-therapy-area-urology","medtech-geography-asia-pacific","medtech-date-2294"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/229167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/229167\/revisions"}],"predecessor-version":[{"id":571871,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/229167\/revisions\/571871"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=229167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}